Physician profile
Jeremy L Rosiecki
NPI 1396138434
$92,598.21
in general payments reported to CMS, 2019-2025
74 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $19K · 2023: $14K · 2024: $24K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $12K · Food and Beverage: $11K · Consulting Fee: $11K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,528.83 |
| Travel and Lodging | $11,926.89 |
| Food and Beverage | $10,582.42 |
| Consulting Fee | $10,563.00 |
| Education | $210.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41,492.21 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Abbvie INC. | $10,365.90 | 2022-2025 | |
| Incyte Corporation | $9,281.36 | 2021-2025 | Monjuvi, Pemazyre, Monjuvi |
| Genmab U.S., INC. | $9,144.21 | 2023-2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $6,101.14 | 2021-2025 | Libtayo |
| Celgene Corporation | $2,216.25 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $1,720.24 | 2021-2025 | Tecvayli, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $1,362.23 | 2023-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $1,351.14 | 2021-2025 | Venclexta, Polivy, Alecensa |
| Astrazeneca Pharmaceuticals Lp | $1,198.50 | 2021-2025 | Calquence, Enhertu, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $1,117.74 | 2021-2023 | Imbruvica, Epkinly |
| Genentech, INC. | $750.00 | 2023 | Lunsumio, Columvi |
| Novartis Pharmaceuticals Corporation | $662.68 | 2022-2025 | |
| Pfizer INC. | $543.64 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $449.24 | 2022-2025 | Erleada, Balversa, Tecvayli |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $350.78 | 2021-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.01 | 2021-2025 | Gilotrif |
| Seagen INC. | $230.95 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Caris Mpi, INC. | $230.39 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $229.67 | 2021-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $216.07 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Aveo Pharmaceuticals, INC. | $200.40 | 2021-2025 | Fotivda |
| Emd Serono, INC. | $195.19 | 2021-2025 | |
| Beone Medicines USA, INC. | $166.94 | 2025 | Brukinsa, Tevimbra |
| Amgen INC. | $161.27 | 2021-2022 | |
| Genzyme Corporation | $160.71 | 2021-2025 | |
| Astellas Pharma US INC | $141.63 | 2021-2025 | Vyloy, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $141.62 | 2023-2025 | Ninlaro, Fruzaqla |
| Jazz Pharmaceuticals INC. | $118.80 | 2021-2022 | |
| Array Biopharma INC | $115.92 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Blueprint Medicines Corporation | $113.43 | 2021-2025 | Ayvakit |
| Exelixis INC. | $99.66 | 2024-2025 | Cabometyx |
| Intuitive Surgical, INC. | $95.81 | 2023 | Da Vinci Surgical System |
| Mirati Therapeutics, INC. | $91.52 | 2023-2024 | Krazati |
| Lilly USA, LLC | $86.48 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $84.68 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.14 | 2021-2024 | |
| Stemline Therapeutics INC. | $82.18 | 2024-2025 | Orserdu, Elzonris |
| Adc Therapeutics America, INC. | $70.29 | 2024-2025 | |
| Sobi, INC | $56.88 | 2022-2024 | |
| Beigene USA, INC. | $51.87 | 2023-2024 | Tevimbra, Brukinsa |
| Acrotech Biopharma INC. | $51.00 | 2021-2024 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $47.07 | 2022-2023 | Qinlock |
| Kite Pharma, INC. | $44.18 | 2021-2022 | |
| Spectrum Pharmaceuticals INC. | $41.74 | 2024 | Rolvedon |
| Geron Corporation | $40.79 | 2024-2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $38.13 | 2022-2023 | Pyrukynd |
| Coherus Oncology, INC. | $37.36 | 2021-2023 | |
| Eisai INC. | $37.18 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $36.61 | 2021-2025 | |
| Myovant Sciences INC. | $35.85 | 2021 | |
| Dendreon Pharmaceuticals LLC | $35.81 | 2023-2024 | Provenge |
| Legend Biotech USA INC. | $34.04 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $30.09 | 2021 | |
| Tersera Therapeutics LLC | $29.75 | 2023 | Zoladex |
| Karyopharm Therapeutics INC. | $28.51 | 2022 | |
| Recordati_rare_diseases_inc. | $25.98 | 2023 | Sylvant |
| Accord Healthcare, INC. | $24.72 | 2025 | |
| G1 Therapeutics, INC. | $24.39 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.23 | 2024 | Pedmark |
| Chiesi USA, INC. | $24.15 | 2021 | |
| Kyowa Kirin, INC. | $22.39 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $22.36 | 2023 | Onivyde |
| Springworks Therapeutics, INC. | $21.49 | 2025 | Gomekli |
| Rigel Pharmaceuticals, INC. | $21.34 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmaessentia USA Corporation | $20.42 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $19.25 | 2025 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $18.25 | 2022 | |
| Foundation Medicine, INC. | $18.13 | 2023 | |
| Octapharma USA, INC. | $17.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.25 | 2024 | |
| Epizyme, INC. | $15.57 | 2021 | |
| Fresenius Kabi USA, LLC | $15.12 | 2023 | Stimufend |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Rosiecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.